Core Viewpoint - The company expects a significant decline of over 50% in net profit for the year 2025 compared to the previous year, primarily due to a high base effect from one-time investment gains in the prior period [1][2]. Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated positive net profit but a substantial decrease [1]. - The company has communicated with its accounting firm regarding the performance forecast, and there are no discrepancies between the two parties [1]. Reasons for Performance Changes - The group has seen significant growth in the global heparin market, with steady sales performance across regions and a continuous increase in market share, particularly with double-digit growth in enoxaparin sales [2]. - The decline in net profit attributable to shareholders is mainly due to a one-time investment gain exceeding RMB 350 million in the same period last year, creating a high comparative base [2]. - Despite the expected impact from joint ventures due to unmet R&D progress, the company has achieved growth in net profit after excluding non-recurring gains, driven by steady increases in main business revenue and profit [2]. Other Relevant Information - The performance forecast is based on preliminary calculations by the company's finance department, and specific financial data will be confirmed in the 2025 annual report [3].

Core Viewpoint - The company Haipru (002399) has disclosed its earnings forecast for 2025, expecting a significant decline in net profit attributable to shareholders, while projecting an increase in non-recurring net profit [2] Financial Performance - The forecasted net profit for 2025 is estimated to be between 284 million yuan and 377 million yuan, representing a year-on-year decrease of 41.71% to 56.09% [2] - The projected non-recurring net profit is expected to be between 362 million yuan and 460 million yuan, indicating a year-on-year growth of 42.78% to 81.43% [2] - Basic earnings per share are estimated to be between 0.1936 yuan and 0.2569 yuan [2] Valuation Metrics - As of January 30, the company's price-to-earnings ratio (TTM) is approximately between 48.14 and 63.91 times, with a price-to-book ratio (LF) of about 1.47 times and a price-to-sales ratio (TTM) of around 3.36 times [2] Business Overview - The company primarily operates in the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs, aiming to provide high-quality and effective medications and services globally [10] - The company has achieved significant results in expanding its heparin product market, with steady sales growth across various regions and a continuous increase in market share [10] Profitability Trends - The decline in net profit attributable to shareholders is mainly due to a high base from the previous year, which included over 350 million yuan in one-time investment income [10] - The company's joint ventures are expected to impact net profit due to unmet research and development progress, with the final impact to be confirmed by the accounting firm [10]

Core Viewpoint - The company, Hepalink (09989), expects a significant decline in net profit attributable to shareholders for the year ending December 31, 2025, projecting between RMB 284 million and RMB 377 million, representing a year-on-year decrease of 41.71% to 56.09% [1] Group 1: Financial Performance - The company reported notable growth in the global heparin product market, with steady sales performance across regions and an increase in market share, particularly with a double-digit growth in enoxaparin sales [1] - The decline in net profit is primarily attributed to a high base from the previous year, which included a one-time investment gain exceeding RMB 350 million [1] - The company's net profit, excluding non-recurring items, showed growth compared to the previous year, driven by steady increases in main business revenue and profit [1] Group 2: Operational Efficiency - The company has been enhancing financial management and optimizing resource allocation to improve operational efficiency and drive continuous improvement in profitability [1] - Despite the anticipated impact from the joint venture's underperformance in R&D, the company still achieved steady growth in net profit after excluding non-recurring items, demonstrating resilience and sustained growth capability in its core business [1]

Summary of the Conference Call for Jianyou Co., Ltd. Industry and Company Overview - Jianyou Co., Ltd. is a leading integrated player in the heparin raw materials and formulations industry, benefiting from a stabilized recovery in heparin raw material prices and solidifying profitability in traditional business segments [2][5][6]. Core Insights and Arguments - **High-end Injection Export Growth**: The high-end injection segment is identified as the second growth engine for Jianyou. The approval of Enoxaparin formulations in the US and European markets has led to rapid growth, with 82 US-approved varieties expected by the end of 2024 [2][6]. - **Expansion in Non-Heparin Products**: Jianyou is expanding its product pipeline in the non-heparin sector, averaging about 10 new ANDA varieties annually. The company is positioned to capture a larger market share, with significant growth potential compared to leading companies like Hikma [2][7]. - **Cost Advantages**: Chinese companies, including Jianyou, have a significant advantage in comprehensive manufacturing costs, which is expected to lead to higher profitability levels as they catch up with competitors like Hikma [2][7]. - **Biologics and Biosimilars Strategy**: Jianyou is strategically positioning itself in the biosimilars and innovative biologics sectors, leveraging its injection export resources. The US biosimilars market is projected to exceed $40 billion by 2027, presenting substantial growth opportunities [2][9]. - **Future Profitability Expectations**: The company is projected to achieve a net profit of approximately 1 billion yuan in 2025, supported by clear international growth potential in high-end formulations and favorable industry policies [3][10]. Additional Important Points - **Historical Context and Growth Model**: Jianyou has a rich history dating back to 1991, with a proven growth model and core competencies that have been validated over time. The current stock price is at a historical low, suggesting a potential investment opportunity [4]. - **Integrated Business Model**: The company has established a comprehensive business model that encompasses research, production, and sales in the heparin raw materials sector, which has solidified its market position [5]. - **Market Penetration Strategy**: Jianyou has successfully established a local marketing system in the US through strategic acquisitions, enhancing its brand influence and market share [6]. This summary encapsulates the key points discussed in the conference call, highlighting Jianyou Co., Ltd.'s strategic positioning, growth potential, and market dynamics.

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 高端注射剂平台建成，健友股份 3.0 To 2030 。 健友股份的前身健友生化厂于 1991 年成立，在创立以来三十余年的时间，公司始终保持 着前瞻的战略眼光和高效的执行力。目前健友股份产品管线丰富，业务涵盖无菌注射剂、肝素原料药、 CDMO 及生物药创新，立足中 美，拓展全球。回顾公司的发展历程，我们认为公司的成长模式和核心竞争力均已得到了较为充分的验证，并展现出广阔的成长空间。 原料药制剂一体化：肝素价稳筑基，制剂蓄势待发 。 健友股份作为国内肝素原料药及制剂一体化的龙头企业，凭借其在肝素产业链上的 完整布局，奠定了公司发展的坚实基础。公司不仅在肝素原料药领域占据重要地位，也通过制剂一体化战略，形成了从研发、生产到销 售的完整产业链条。 制剂出口 1 ：依诺肝素开篇，高端注射剂接力。 公司以依诺肝素制剂全球化突破为起点 ...

Core Viewpoint - The article emphasizes the growth potential and strategic positioning of Jianyou Co., highlighting its comprehensive capabilities in high-end injectable drugs and the integration of raw materials and formulations, particularly in the heparin sector, as well as its expansion into biosimilars and innovative drugs. Group 1: High-End Injectable Drug Platform - Jianyou Co. has established a high-end injectable drug platform, showcasing a rich product pipeline that includes sterile injectables, heparin raw materials, CDMO, and biopharmaceutical innovations, with a focus on expanding globally from a strong base in China and the U.S. [2][6] - The company has a solid foundation in the heparin industry, being a leading player in the integrated raw material and formulation sector, which supports its growth trajectory [16][20]. Group 2: Export of Formulations - The company has successfully launched its enoxaparin formulations globally since 2019, becoming a key driver of overseas revenue growth, leveraging FDA/EMA certifications to access emerging markets [29][30]. - As of the end of 2024, Jianyou Co. has obtained 82 approved ANDA products in the U.S., with plans to accelerate penetration into Europe and emerging markets [29][35]. Group 3: Biosimilars and Innovative Drugs - Jianyou Co. is transitioning towards biosimilars and innovative drugs, capitalizing on its manufacturing expertise to explore broader market opportunities, particularly in the U.S. biosimilar market, which is projected to exceed $40 billion by 2027 [4][53]. - The company has made strategic acquisitions, such as the purchase of Coherus' adalimumab biosimilar, to enhance its market position in the U.S. [62]. Group 4: Financial Performance and Projections - For the first three quarters of 2024, the company reported revenues of 3.088 billion yuan, with a net profit of 606 million yuan, reflecting a year-on-year decline of 27.83% [10]. - The projected net profits for 2024-2026 are 816 million, 1.108 billion, and 1.478 billion yuan, respectively, indicating a recovery and growth trajectory [4][10]. Group 5: Market Position and Competitive Landscape - The U.S. injectable generic drug market is characterized by high barriers to entry, with significant growth potential, as evidenced by the market size of $15-20 billion and a projected CAGR in the high single digits [37][49]. - Jianyou Co. is positioned to compete effectively against established players like Hikma, with a focus on leveraging its integrated manufacturing and cost advantages to enhance profitability [49][50].